Literature DB >> 7979851

Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines.

N Fiebach1, W Beckett.   

Abstract

Influenza and pneumococcal infections are important causes of hospitalization and death among individuals who are elderly or who have chronic illnesses. Influenza and pneumococcal vaccines may prevent these infections and their complications, but most high-risk patients have not received them. Doubts about their effectiveness, fears of side effects, and the lack of programs to promote their use contribute to the underuse of these vaccines. Although adequate controlled trials in high-risk patients are lacking, there is observational evidence that they are moderately effective, reducing serious complications of influenza and pneumococcal infections by about one-half. They are cost-effective compared with other preventive interventions and may be cost saving. Their safety has been demonstrated in numerous studies. Health care providers should promote influenza and pneumococcal vaccination. Strategies that have been shown to be successful in increasing the use of these vaccines include provider education and feedback, flagging charts of vaccination candidates, mailed reminders to patients without fall appointments, standing orders for nurses to administer the vaccines, walk-in vaccination clinics, and vaccination of hospitalized patients at discharge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979851

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

Review 1.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 2.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Evaluating the impact of influenza vaccination. A North American perspective.

Authors:  D S Fedson
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 4.  The value of influenza and pneumococcal vaccines in the elderly.

Authors:  A S Monto; M S Terpenning
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

5.  Pneumococcal vaccine.

Authors:  K L Hattotuwa; C R Hind
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

Review 6.  Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy.

Authors:  C A Mao; E L Siegler; E Abrutyn
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

Review 7.  The cost effectiveness of pneumococcal vaccination strategies.

Authors:  C B Gable; M Botteman; G Savage; K Joy
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

8.  Clinical effectiveness of pneumococcal vaccine. Meta-analysis.

Authors:  B G Hutchison; A D Oxman; H S Shannon; S Lloyd; C A Altmayer; K Thomas
Journal:  Can Fam Physician       Date:  1999-10       Impact factor: 3.275

9.  Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis.

Authors:  Subhashis Mitra; Gary E Stein; Shyam Bhupalam; Daniel H Havlichek
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

10.  Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands.

Authors:  E Hak; G A van Essen; E Buskens; W Stalman; R A de Melker
Journal:  J Epidemiol Community Health       Date:  1998-02       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.